Jingyu Zhao, MS
In Vivo CAR T Cell Engineering for More Effective, Affordable Cancer Treatment
Abstract
Chimeric antigen receptor (CAR) T cell therapy is a powerful treatment for several blood cancers that works by reprogramming a patient’s own T cells to find and kill cancer cells. However, the process of extracting the patient’s T cells, modifying them in a lab, and then reinjecting them into the patient is complicated, time-consuming, and expensive. Our research aims to simplify this process by creating CAR T cells directly inside the patient. We will use viruses specially engineered to safely deliver the CAR gene to the patient’s T cells. To improve the efficacy, we also combine the virus with certain chemicals that enhance its effectiveness. In preliminary studies, this system successfully produced CAR T cells and eliminated B cell lymphoma tumors in animal models. We are now testing this system against different solid tumors, such as lung cancer and pancreatic cancer, in animal models, evaluating its effectiveness, safety, and potential side effects. If successful, this approach could make CAR T cell therapy more accessible and affordable for patients.
I am deeply honored to receive the PhRMA Foundation Fellowship and to connect with peers and experts in this community. This will further inspire me to advance my research on a cost-effective and efficient gene-engineering strategy for cancer immunotherapy, ultimately benefiting more patients.
